SCHEMBL13216367

SCHEMBL13216367

COC(=O)COc1cccc(C2(CC(=O)O)C3CC4CC(C3)CC2C4)c1

nearest known ligand 0.59

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 12/20 0.59
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ALOX5AP P20292 2/20 0.42
LMNA P02545 1/20 0.41
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13216108 0.90 HSD11B1 (0.65) HSD11B1MEN1KMT2ALMNA
SCHEMBL3023608 0.86 HSD11B1 (0.72) HSD11B1MEN1KMT2ALMNAALDH1A1
SCHEMBL13216106 0.77 HSD11B1 (0.71) HSD11B1MEN1KMT2A
SCHEMBL3025215 0.76 HSD11B1 (0.73) HSD11B1MEN1KMT2A
SCHEMBL7813280 0.75 HSD11B1 (1.00) HSD11B1MEN1KMT2A
SCHEMBL13216326 0.74 HSD11B1 (1.00) HSD11B1MEN1KMT2A
SCHEMBL13216344 0.74 HSD11B1 (1.00) HSD11B1MEN1KMT2AALDH1A1
SCHEMBL13216336 0.73 HSD11B1 (1.00) HSD11B1MEN1KMT2A
SCHEMBL3029567 0.72 HSD11B1 (1.00) HSD11B1MEN1KMT2A
SCHEMBL4076916 0.72 LMNA (0.62) MEN1KMT2ALMNAALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2054368-B1 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-09-16 EP disclosed
US-8299054-B2 Cyclic 11-beta hydroxysteroid dehydrogenase type 1 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-10-30 US disclosed
US-8299054-B2 Cyclic 11-beta hydroxysteroid dehydrogenase type 1 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-10-30 US disclosed
US-20100204199-A1 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-08-12 US disclosed
US-20100204199-A1 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-08-12 US disclosed
US-7727978-B2 Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-06-01 US disclosed
US-7727978-B2 Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-06-01 US disclosed
US-20080234249-A1 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2008-09-25 US disclosed
US-20080234249-A1 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2008-09-25 US disclosed
WO-2008024892-A2 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234249-A1 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885MEN1 994/4885KMT2A 3725/4885
US-20100204199-A1 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885MEN1 994/4885KMT2A 3725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.